Cumberland Emerging Technologies Appoints a New Senior Executive

Submitted by Cumberland Pharma on Thu, 10/03/2019 - 06:00

 

Cumberland Emerging Technologies, or CET, is a joint initiative between Cumberland Pharmaceuticals, Vanderbilt University, LaunchTN, and Winhealth Pharma Group. Its mission is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace.

 

Orphan Drug Grant Funding for New Clinical Program!

Submitted by Cumberland Pharma on Tue, 09/24/2019 - 15:00

 

We’ve initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. FDA has cleared our application to study ifetroban in DMD patients, 7 years of age and older.

 

Pages